Psychopharmacological treatment of non-suicidal self-injury;Psychopharmakologische behandlung von nicht suizidalem selbstverletzendem verhalten

Nervenheilkunde

Volumn 32, Issue 1-2, 2013, Pages 38-44

  Plener, P L ^a   Libal, G ^b   Fegert, J M ^a   Kolch M G ^a,c  

^a UNIVERSITY OF ULM   (Germany)

^b Uni Ulm   (Germany)

^c Vivantes Kliniken für Kinder und Jugendpsychiatrie Psychotherapie und Psychosomatik   (Germany)

Author keywords

Atypical antipsychotics; Non suicidal self injury; Psychopharmacology; Selective serotonin reuptake inhibitors; Suicidality

Indexed keywords

OPIATE ANTAGONIST; SEROTONIN UPTAKE INHIBITOR;

ARTICLE; AUTOMUTILATION; DRUG EFFICACY; EVIDENCE BASED MEDICINE; HUMAN; MEDICAL LITERATURE; NONSUICIDAL SELF INJURY; PSYCHOPHARMACOLOGY; PSYCHOTHERAPY; SUICIDE; SYSTEMATIC REVIEW;

EID: 84874855774     PISSN: 07221541     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-0038-1628475     Document Type: Article

References (80)

1. Nock MK. Self-injury. Annual Review of Clinical Psychology 2010; 6: 339-63.
2. Stanford S et al. Psychological subtyping finds pathological, impulsive, and 'normal' groups among adolescents who self-harm. Journal of Child Psychology and Psychiatry 2009; 50: 807-15.
3. Favazza AR. Repetitive Self-Mutilation. Psychiatric Annals 1992; 22: 60-3.
4. Sandman CA. Psychopharmacologic treatment of nonsuicidal self-injury. In: Nock MK (Ed.), Understanding nonsuicidal self-injury. Origins, Assessment, and Treatment. Washington D.C.: American Psychological Association 2009; 291-323.
5. Parikh MS et al. Psychopharmacology of aggression in children and adolescents with autism: A critical review of efficacy and tolerability. Journal of Child and Adolescent Psychopharmacology 2008; 18: 157-78.
6. Häßler F et al. Psychopharmacological therapy of self-injurious behavior in mentally retarded individuals. Nervenarzt 1999; 70: 1025-8.
7. Lloyd-Richardson EE et al. Characteristics and functions of non-suicidal self-injury in a community sample of adolescents. Psychological Medicine 2007; 37: 1183-92.
8. Mercer D et al. Meta-Analyses of mood stabilizers, antidepressants and antipsychotics in the treatment of borderline personality disorder: Effectiveness for depression and anger symptoms. Journal of Personality Disorders 2009; 23: 156-74.
9. Plener PL et al. Use of medication in the treatment of nonsuicidal self-injury in youth. In Nixon MK, Heath NL (Eds.), Self-Injury in Youth. New York: Routledge 2009; 275-309.
10. Harper G. Psychopharmacological treatment. In Walsh BW (Ed.), Treating Self-Injury. A Practical Guide. New York: Guilford Press 2006; 212-20.
11. Soomro GM. Deliberate self-harm (and attempted suicide). Clin Evid (Online) 2008; pii: 1012.
12. Smith BD. Self-mutilation and pharmacotherapy. Psychiatry 2005; 10: 29-37.
13. Ingenhoven T et al. Effectiveness of pharamcotherapy for severe personality disorders: metaanalysis of randomized controlled trials. J Clin Psychiatry 2010; 71: 14-25.
14. Bloom CM et al. Toward new avenues in the treatment of nonsuicidal self-injury. J Pharm Pract 2011; 24: 472-77.
15. Ripoll LH et al. Evidence-based pharmacotherapy for personality disorders. International Journal of Neuropsychopharmacology 2011; 14: 1257-88.
16. Pies RW et al. Self-injurious behavior: Pathophysiology and implications for treatment. Journal of Clinical Psychiatry 1995; 56: 580-8. (Pubitemid 26002164)
17. Roberts N. Adolescent self-mutilatory behavior: Psychopharmacological treatment. Child and Adolescent Psychopharmacology News 2003; 8: 10-2.
18. Groschwitz RC et al. The neurobiology of non-suicidal. Suicidology Online 2012; 3: 24-32.
19. Verkes RJ et al. Reduction by paroxetine of suicidal behavior in patients with repeated suicide attempts but not major depression. American Journal of Psychiatry 1998; 155: 543-7. (Pubitemid 28207452)
20. Simpson EB et al. Combined dialectical behavior therapy and fluoxetine in the treatment of borderline personality disorder. Journal of Clinical Psychiatry 2004; 65: 379-85.
21. Markovitz PJ et al. Fluoxetine in the treatment of Borderline and Schizotypal Personality Disorders. American Journal of Psychiatry 1991; 18: 1064-67.
22. Hawton KKE et al. Psychosocial and pharmacological treatments for deliberate self harm. The Cochrane library 2009; 1-42.
23. Fegert JM. Depressionsbehandlung mit SSRI in der Kinder-und Jugendpsychiatrie. Ein Forschungs-oder ein Informationsdebakel? Nervenheilkunde 2004; 23: 1-67.
24. Brent DA. Antidepressants and pediatric depression-The risk of doing nothing. New England Journal of Medicine 2004; 351: 1598-1601.
25. Whittington CJ et al. Selective Serotonin Reuptake Inhibitors in childhood depression: Systematic review of published versus unpublished data. The Lancet 2004; 36: 1341-5. (Pubitemid 38529872)
26. Nemeroff CB et al. Impact of publicity concerning pediatric suicidality data on physician practice patterns in the United States, Archives of General Psychiatry 2007; 64: 466-72.
27. Hammad TA. www.fda.gov/ohrms/dockets/ac/ 04/briefing/2004-4065b1-10- TAB08-Hammads-Review.pdf. 2004.
28. Didham RC et al. Suicide and self-harm following prescription of SSRIs and other antidepressants: confounding by indication. Br J Clin Pharmacol 2005; 60: 519-525.
29. Teicher MH et al. Antidepressant drugs and the emergence of suicidal tendencies. Drug Safety 1993; 8: 186-212.
30. Donovan S et al. Deliberate self-harm following antidepressant drugs. British Journal of Psychiatry 2000; 177: 551-6.
31. Goodyer I et al. Selective serotonin reuptake inhibitors (SSRIs) and routine specialist care with and without cognitive behaviour therapy in adolescents with major depression: Randomised controlled trial. British Medical Journal 2007; 335: 142-50.
32. Brent DA et al. Switching to another SSRI or to venlafaxine with or without cognitive behavioural therapy for adolescents with SSRI-resistant depression: The TORDIA randomized controlled trial. Journal of the American Medical Association 2008; 299: 901-13.
33. Brent DA et al. Predictors of spontaneous and systematically assessed suicidal adverse events in the treatment of SSRI-resistant depression in adolescents (TORDIA) study. American Journal of Psychiatry 2009; 166: 418-26.
34. Wöckel L et al. Psychopharmakotherapie einer ambulanten und stationären Inanspruchnahmepopulation adoleszenter Patienten mit Borderline Persönlichkeitsstörung. Z Kinder Jugendpsychiatr Psychother 2010; 38: 37-49.
35. Kölch M et al. Verhaltensaktivierung durch SSRI als Gefahr für Amoktaten von Jugendlichen? Nervenheilkunde 2010; 29: 451-5.
36. Gibbons RD et al. Suicidal thoughts and behaviour with antidepressant treatment. Arch Gen Psychiatry 2012; Epub ahead of print: doi:10.1001/ archgenpsychiatry.2011.2048.
37. Grootens KP et al. Emerging evidence for the use of atypical antipsychotics in borderline personality disorder. Pharmacopsychiatry 2005; 38: 20-3. (Pubitemid 40278642)
38. Abraham PF et al. Evidenced-based pharmacologic treatment of borderline personality disorder: A shift from SSRIs to anticonvulsants and atypical antipsychotics? Journal of Affective Disorders 2008; 111: 21-30.
39. Schulz SC et al. Olanzapine for the treatment of boderline personality disorder: Variable dose 12-week randomised double-blind placebo-controlled study. British Journal of Psychiatry 2008; 193: 485-92.
40. Linehan MM et al. Olanzapine plus dialectical behaviour therapy for women with high irritability who meet criteria for borderline personality disorder: A double-blind, placebo-controlled pilot study. Journal of Clinical Psychiatry 2008; 69: 999-1005.
41. Soler J et al. Double-blind, placebo-controlled study of Dialectical Behavior Therapy plus olanzapine for Borderline Personality disorder. Am J Psychiatry 2005; 162: 1221-4. (Pubitemid 40770712)
42. Chengappa KNR et al. Clozapine reduces severe self-mutilation and aggression in psychotic patients with Borderline Personality disorder. Journal of Clinical Psychiatry 1999; 60: 477-84.
43. Hilger E et al. Quetiapine in the treatment of borderline personality disorder. World Journal Biological Psychiatry 2003; 4: 42-4.
44. Nickel MK et al. Aripiprazole in the treatment of patients with borderline personality disorder: A double-blind, placebo-controlled study. American Journal of Psychiatry 2006; 163: 833-8. (Pubitemid 44464531)
45. Nickel MK et al. Aripiprazole in treatment of borderline patients, part II: An 18-month follow-up. Psychopharmacology 2007; 191: 1023-26.
46. Good CR. Adjunctive Quetiapine targets selfharm behaviors in adolescent females with major depressive disorder. Journal of Child and Adolescent Psychopharmacology 2006; 16: 235-6. (Pubitemid 43902419)
47. Libal G et al. Ziprasidone as a weight-neutral treatment alternative in the treatment of self-injurious behavior in adolescent females. Child and Adolescent Psychopharmacology News 2005; 10: 1-6.
48. Cordàs TA et al. Oxacarbazepine for self-mutilating bulimic patients. International Journal of Neuropsychopharmacology 2006; 9: 769-71.
49. Bellino S et al. Oxcarbazepine in the treatment of borderline personality disorder: A pilot study. Journal of Clinical Psychiatry 2005; 66: 1111-5. (Pubitemid 41442276)
50. Cassano P et al. Topiramate for self-mutilation in a patient with borderline personality disorder. Bipolar Disorders 2001; 3: 161. (Pubitemid 32611446)
51. Pittenger C et al. Initial evidence of the beneficial effects of glutamate-modulating agents in the treatment of self-injurious behavior associated with borderline personality disorder. J Clin Psychiatry 2005; 66: 1492-3. (Pubitemid 41779556)
52. Kapusta ND et al. Lithium in drinking water and suicide mortality. Br J Psychiatry 2011; 198: 346-50.
53. Masters KJ. Anti-suicidal and self-harm properties of lithium carbonate. CNS Spectrums 2008; 13: 109-10.
54. Philipsen, A et al. Clonidine in acute aversive inner tension and self-injurious behavior in female patients with borderline personality disorder. Journal of Clinical Psychiatry 2004; 65: 1414-19.
55. Osuch EA et al. Neurobiological perspectives on Self-injury. In Nixon MK, Heath NL (eds.), Self-Injury in Youth. New York London: Routledge 2009; 79-111.
56. Sher L et al. Biological Models of Nonsuicidal Self-Injury. In: Nock MK (Ed.). Understanding Nonsuicidal Self-Injury. Origins, Assessment, and Treatment. Washington D.C.: American Psychological Association 2009; 99-117.
57. Stanley B et al. Non-suicidal self-injurious behavior, endogenous opioids and monoamine neurotransmitters. J Affect Disord 2010; 124: 134-40.
58. Sandman CA. The opiate hypothesis in autism and self-injury. Journal of Child and Adolescent Psychopharmacology 1990/91; 1: 193-99.
59. Symons FJ et al. Self-injurious behaviour and the efficacy of naltrexone treatment: A quantitative synthesis. Mental Retardation and Developmental Disabilities Research Reviews 2004; 10: 193-200.
60. Roth AS et al. Naltrexone as a treatment for repetitive self-injurious behaviour: An open-label trial. Journal of Clinical Psychiatry 1996; 57: 233-37.
61. Griengl H et al. Naltrexone as a treatment of selfinjurious behavior-A case report. Acta Psychiatrica Scandinavica 2001; 103: 234-6. (Pubitemid 32154357)
62. Mc Gee MD. Cessation of self-mutilation in a patient with borderline personality disorder treated with naltrexone. Journal of Clinical Psychiatry 1997; 58: 32-33. (Pubitemid 27089719)
63. Sonne S et al. Naltrexone treatment of self-injurious thoughts and behaviours. Journal of Nervous and Mental Disease 1996; 184: 192-5. (Pubitemid 26112940)
64. Cowdry RW et al. Pharmacotherapy for Borderline Personality Disorder. Archives of General Psychiatry 1988; 45: 111-9.
65. Rothschild AJ et al. Comparison of the frequency of behavioural disinhibition on alprazolam, clonazepam, or no benzodiazepine in hospitalized psychiatric patients. Journal of Clinical Psychopharmacology 2000; 20: 7-11. (Pubitemid 30056347)
66. Berman ME et al. The effects of diazepam on human self-Aggressive behaviour. Psychopharmacology (Berl.) 2005; 178: 100-6. (Pubitemid 40298697)
67. Owen C et al. The role of fatty acids in the development and treatment of mood disorders. Current Opinion in Psychiatry 2008; 21: 19-24.
68. Garland MR et al. Lipids and essential fatty acids in patients presenting with self-harm. British Journal of Psychiatry 2007; 190: 112-7.
69. Hallahan B et al. Omega-3 fatty acid supplementation in patients with recurrent self-harm. British Journal of Psychiatry 2007; 190: 118-22.
70. Harbour R et al. A new system for grading recommendations in evidence based guidelines. British Medical Journal 2001; 323: 334-6. (Pubitemid 32744465)
71. Nose M et al. Efficacy of pharmacotherapy against core traits of borderline personality disorder: Meta-Analysis of randomized controlled trials. International Clinical Psychopharmacology, 2006; 21: 345-53.
72. Villalba R et al. Repetitive self-injurious behavior: A neuropsychiatric perspective and review of pharmacologic treatments. Seminars in Clinical Neuropsychiatry 2000; 5: 215-26.
73. Nitkowski D et al. Behavioural analysis of self-injurious behaviour. Nervenheilkunde 2009; 28: 227-31.
74. Katz LY et al. The role of behavioral analysis in the pharmacotherapy of emotionally-dysregulated problem behaviors. Child and Adolescent Psychopharmacology News 2005; 10: 1-5.
75. Mobascher A et al. Behandlung der Borderline Persönlichkeitsstö rung mit atypischen Antipsychotika. Nervenarzt 2007; 78: 1003-13.
76. Plener PL et al. Non-suicidal self-injury as autonomous diagnosis-implications for research and clinic of the DSM-5 proposal to establish the diagnosis of Non-Suicidal Self-Injury in adolescents. Z Kinder Jugendpsychiatr Psychother 2012; 40: 113-20.
77. Whitlock J et al. The relationship between self-injurious behaviour and suicide in a young adult population. Archives of Pediatric and Adolescent Medicine 2007; 161: 634-40.
78. Andover MS et al. The co-occurrence of non-suicidal self-injury and attempted suicide among adolescents: distinguishing risk factors and psychosocial correlates. Child and Adolescent Psychiatry and Mental Health 2012; 6: 11.
79. Shaffer D et al. Proposal to the DSM-V Childhood Disorder and Mood Disorder Work Groups to Include Non-Suicidal Self-Injury (NSSI) as a DSM-V Disorder. www.dsm5.org/Proposed%20Revi sion%20Attachments/APA%20DSM- 5%20NSSI%20Proposal.pdf. 2009.
80. Groschwitz R, Plener PL. Psychotherapie von nicht suizidalem selbstverletzendem Verhalten. Nervenheilkunde 2013: 32: 30-36.